Next Article in Journal
MCP-1 rs1024611 Polymorphism, MCP-1 Concentrations, and Premature Coronary Artery Disease: Results of the Genetics of Atherosclerotic Disease (GEA) Mexican Study
Next Article in Special Issue
Extracellular Vesicles and Immune System Function: Exploring Novel Approaches to Colorectal Cancer Immunotherapy
Previous Article in Journal
Does Transcranial Direct Current Stimulation Affect Potential P300-Related Events in Vascular Dementia? Considerations from a Pilot Study
Previous Article in Special Issue
Exploring the Potential of Humoral Immune Response to Commensal Bifidobacterium as a Biomarker for Human Health, including Both Malignant and Non-Malignant Diseases: A Perspective on Detection Strategies and Future Directions
 
 
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Systematic Review

Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review

by
Milan Daniel Velimirovici
1,
Catalin Vladut Ionut Feier
2,3,
Razvan Constantin Vonica
4,*,
Alaviana Monique Faur
5 and
Calin Muntean
6
1
Doctoral School, “Victor Babes” University of Medicine and Pharmacy, 2 E. Murgu Sq., 300041 Timisoara, Romania
2
First Discipline of Surgery, Department X-Surgery, “Victor Babes” University of Medicine and Pharmacy, 2 E. Murgu Sq., 300041 Timisoara, Romania
3
First Surgery Clinic, “Pius Brinzeu” Clinical Emergency Hospital, 300723 Timisoara, Romania
4
Preclinical Department, Discipline of Physiology, Faculty of General Medicine, “Lucian Blaga” University of Sibiu, 550169 Sibiu, Romania
5
Faculty of Medicine, Victor Babes” University of Medicine and Pharmacy, 2 E. Murgu Sq., 300041 Timisoara, Romania
6
Medical Informatics and Biostatistics, Department III-Functional Sciences, “Victor Babes” University of Medicine and Pharmacy, 2 E. Murgu Sq., 300041 Timisoara, Romania
*
Author to whom correspondence should be addressed.
Biomedicines 2024, 12(6), 1291; https://doi.org/10.3390/biomedicines12061291
Submission received: 4 May 2024 / Revised: 7 June 2024 / Accepted: 10 June 2024 / Published: 11 June 2024
(This article belongs to the Special Issue Recent Advances in Immunotherapy for Solid Tumors)

Abstract

Background and objectives: The efficacy and safety of PD-L1 inhibitors in the treatment of cervical cancer is an ongoing research question. This review aims to establish a clear profile of atezolizumab, examining its impact on survival outcomes, response rates, and safety measured by serious adverse events (SAEs). Materials and methods: A literature search was conducted using PubMed, Scopus, and Web of Science, focusing on articles published up to February 2024. The review followed the PRISMA guidelines and synthesized outcomes from four randomized trial studies involving atezolizumab administered at 1200 mg IV every three weeks, alone or in combination with chemoradiotherapy. Results: A total of 284 patients received atezolizumab, the majority being advanced stage cervical cancer (IVA-IVB). Median follow-up times ranged from 9 weeks to 32.9 months. It was found that combining atezolizumab with standard therapies extended median progression-free survival (PFS) from 10.4 to 13.7 months and overall survival (OS) from 22.8 to 32.1 months, according to the phase III trial. Monotherapy and initial treatment settings with atezolizumab also showed promising efficacy, with disease-free survival rates at 24 months reaching 79% compared to 52% with standard therapy alone. However, the treatment was associated with high rates of SAEs, reaching up to 79% in more intensive treatment combinations. Conclusions: Atezolizumab demonstrates significant potential in improving PFS and OS in patients with cervical cancer, supporting its inclusion as a first-line treatment option. Despite the efficacy benefits, the high incidence of SAEs necessitates careful patient selection and management strategies to mitigate risks. This systematic review supports the continued evaluation of atezolizumab in broader clinical trials to refine its therapeutic profile and safety measures in the context of cervical cancer treatment.
Keywords: oncology; gynecology; cervical cancer; systematic review oncology; gynecology; cervical cancer; systematic review

Share and Cite

MDPI and ACS Style

Velimirovici, M.D.; Feier, C.V.I.; Vonica, R.C.; Faur, A.M.; Muntean, C. Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review. Biomedicines 2024, 12, 1291. https://doi.org/10.3390/biomedicines12061291

AMA Style

Velimirovici MD, Feier CVI, Vonica RC, Faur AM, Muntean C. Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review. Biomedicines. 2024; 12(6):1291. https://doi.org/10.3390/biomedicines12061291

Chicago/Turabian Style

Velimirovici, Milan Daniel, Catalin Vladut Ionut Feier, Razvan Constantin Vonica, Alaviana Monique Faur, and Calin Muntean. 2024. "Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review" Biomedicines 12, no. 6: 1291. https://doi.org/10.3390/biomedicines12061291

APA Style

Velimirovici, M. D., Feier, C. V. I., Vonica, R. C., Faur, A. M., & Muntean, C. (2024). Efficacy and Safety of Atezolizumab as a PD-L1 Inhibitor in the Treatment of Cervical Cancer: A Systematic Review. Biomedicines, 12(6), 1291. https://doi.org/10.3390/biomedicines12061291

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop